Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study
Status:
Unknown status
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Efficacy of monthly intravitreal anti-vascular endothelial growth factor (VEGF) associated to
systemic immunosuppression in patients with Vogt-Koyanagi-Harada Disease and choroidal
neovascularization. Minimum follow-up 12 months. Endpoints: 6 and 12 months of follow-up.
Outcome measures: improvement of VA, decrease in central foveal thickness as measured by
Optical Coherence Tomography (OCT) and absence of intra/subretinal fluid.
Phase:
N/A
Details
Lead Sponsor:
University of Sao Paulo
Collaborator:
Fundação de Amparo à Pesquisa do Estado de São Paulo